Combined antiretroviral treatment and heterosexual transmission of HIV-1: cross sectional and prospective cohort study by Del Romero, Jorge et al.
RESEARCH
Combined antiretroviral treatment and heterosexual
transmission of HIV-1: cross sectional and prospective
cohort study
Jorge Del Romero, clinicalresearcher,
1Jesu ´sCastilla, consultant medical epidemiologist,
2Victoria Hernando,
epidemiologist,
3 Carmen Rodrı ´guez, research scientist,
1 Soledad Garcı ´a, clinical researcher
1
ABSTRACT
Objective To estimate the risk and probability of
heterosexual transmission of HIV-1 from infected people
taking combined antiretroviral treatment.
Design Cross sectional and prospective cohort studies.
Setting HIV clinic in Madrid, Spain.
ParticipantsStableheterosexualcoupleswithonepartner
withHIV-1infection(indexpartner)andtheotherreporting
this sexual relationship as the only risk exposure.
MainoutcomemeasuresHIVseroprevalenceinnon-index
partners at enrolment and seroconversions in follow-up
according to antiretroviral treatment taken by the index
partner.
ResultsIn476couplesinwhichtheindexpartnerwasnot
taking antiretroviral treatment, HIV seroprevalence at
enrolment in non-index partners was 9.2% (n=44),
whereas in 149 couples in which the index partner was
taking combined antiretroviral therapy no partner was
infected (P<0.001). During follow-up, the 341
serodiscordant couples in which the index partner was
not taking antiretroviral treatment had about 11000 acts
of intercourse without condoms, 50 natural pregnancies,
and five HIV seroconversions (0.0004 per unprotected
intercourse; 95% confidence interval 0.0001 to 0.0010);
294 of these couples always used condoms, accounting
for about 42000 acts of intercourse, 136 risk exposures
from condom failure, and one HIV seroconversion. The
relative risk associated with condom use was 0.07 (0.01
to 0.58). In 144 couples the index partner was taking
combined antiretroviral treatment; they accounted for
over 7000 unprotected acts of intercourse and 47 natural
pregnancies but no HIV seroconversion (0 to 0.0005 per
unprotected intercourse).
Conclusions The heterosexual infectivity of HIV-1 in
individualstakingeffectiveantiretroviraltreatmentislow.
Avoidance of unprotected intercourse and receipt of
antiretroviral treatment by the infected partner in
accordance with protocols are complementary measures
to prevent HIV transmission.
INTRODUCTION
The probability of transmission of HIV-1 during each
sexual contact varies considerably according to the
type of sexual practice, presence of other sexually
transmitted infections, stage of HIV disease, and
plasma HIV RNA concentration in the infected
partner.
1-11
People with a stable heterosexual partner with HIV
are exposed to the risk of infection each time their
mucosa come into contact with their partner’s genital
fluids.Sexualabstinenceistheonlyrisk-freeoptionbut
is not accepted by many partners who try to lead a
normal sexual and reproductive life.
1213 The alterna-
tive is to use condoms in all sexual contacts, but sys-
tematic adherence is difficult for some couples,
impedes natural conception, and does not completely
eliminate the risk of transmission.
14 Combined anti-
retroviral treatment can reduce HIV RNA in both the
plasma
15 and genital fluids of infected people,
1617 and
effective viral suppression has been associated with a
significant reduction of infectivity.
5-7 Some studies
have associated the use of combined antiretroviral
therapy with reduced sexual transmission of HIV,
18-22
but none has established the probability of transmis-
sion in heterosexual relationships when the infected
partner is receiving this treatment.
23
We analysed stable heterosexual couples in which
HIV-1 infection had been diagnosed in one partner
(index partner) and the non-index partner reported
sexual relationship with the index partner as the only
risk exposure. We evaluated HIV seroprevalence in
non-index partners at enrolment, as well as seroinci-
dence and probability of transmission during succes-
sive visits, according to the couple’s sexual risk
exposures and antiretroviral treatment in the index
partner.
METHODS
Setting and study population
Thisstudybeganin1989,atthesametimeasaspecific
programmeforheterosexualHIVserodiscordantcou-
ples was launched in a clinic for HIV and sexually
transmitted infections in Madrid, Spain. Each patient
with a diagnosis of HIV infection was advised that his
or her sexual partner should visit the clinic. The pro-
grammeincludescomprehensivemedicalconsultation
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uled every six months. At each visit, the index partner
undergoes clinical follow-up, the partner is recom-
mended to undergo an HIV test, genitourinary infec-
tions (including sexually transmitted infections,
bacterial vaginosis, and vaginal candidiasis) are ruled
out, and women are offered an annual gynaecological
examination. Access to free antiretroviral treatment is
provided when the index partner meets current inter-
national guidelines.
24 Couples are systematically
advised against having unprotected sex. The staff
responsible for this programme did not change
throughout the study period.
Design and variables
Withtheinformedconsentofbothpartners,stablehet-
erosexualcouplestreatedinthisprogrammewerepro-
spectively included in an observational study to
quantify the risk of heterosexual HIV transmission
according to sexual risk behaviours.
In a cross sectional analysis of HIV seroprevalence,
we included couples recruited in 1989-2008, when the
non-index partner came to the clinic for his or her first
HIV test, who met the following criteria: ongoing sex-
ual relationship during the past six months, the index
partner had received a diagnosis of HIV with a well
identified probable route of infection, and the non-
index partner had no previous HIV diagnosis and no
known risk exposure other than the heterosexual
relationship with the index partner. HIV prevalence
innon-indexpartnerswasevaluatedaccordingtotreat-
ment of the index partner.
We included all heterosexual couples who were ser-
odiscordant for HIV who returned for at least one fol-
low-up visit in a prospective cohort analysis of HIV
seroconversion. Follow-up began on the date of the
first negative HIV test result within the programme,
and the end point was the first HIV-1 positive test
result. For those participants who failed to return for
checkupsformorethan24months,whoserelationship
ended, or whose non-index partner reported any risk
exposure outside the relationship, data were censored
at the last follow-up visit. For the remaining couples,
follow-up was censored at the last check up before 31
December 2008.
We used a series of forms designed at the beginning
of the study to collect epidemiological, clinical, and
sexualbehaviourinformation;theseformsweresubse-
quently modified to incorporate new laboratory tests
and treatments. At all visits trained medical practi-
tioners collected data. They asked non-index partners
aboutthenumberofactsofsexualintercourse(vaginal
and anal) during the previous six months (at the first
visit) or since the previous visit (follow-up). For each
type of practice, respondents reported the number of
protected (with condom) and unprotected contacts
using a semi-quantitative scale (never, less than half
of the times, more than half of the times, and always);
Table 1 |Characteristics of couples enrolled during 1989-2008 according to treatment of index partner. Figures are numbers
(percentages) of participants unless stated otherwise
Total
Antiretroviral treatment*
No treatment
Combined
treatment P value†
All 648 (100) 476 (100) 149 (100)
Male index case 535 (83) 385 (81) 130 (87) 0.08
History of injecting drug use in index case 494 (76) 370 (78) 106 (71) 0.1
Median (IQR) age (years):
Women 29 (25-35) 28 (24-33) 34 (30-39) <0.001
Men 32 (28-37) 30 (27-35) 38 (33-40) <0.001
Median (IQR) duration of relationship (years) 3.1 (1.0-7.6) 2.9 (0.9-7.0) 4.2 (1.4-9.5) 0.004
Median (IQR) known duration of HIV infection (months) 29 (3-94) 13 (1-50) 146 (72-184) <0.001
Began relationship after diagnosis of HIV in index case 281 (43) 164 (34) 103 (69) <0.001
Unprotected penile-vaginal or penile-anal contact in past 6 months 352 (54) 273 (57) 69 (46) 0.02
Unprotected penile-anal contact in past 6 months 93 (14) 79 (17) 12 (8.1) 0.01
Previous pregnancy 286 (44) 226 (47) 53 (36) 0.01
Current pregnancy 42 (6.5) 32 (6.7) 8 (5.4) 0.7
Median (IQR) CD4 cell count ×10
6/l in index partner‡ 500 (295-700) 514 (291-716) 475 (300-660) 0.4
Median (IQR) plasma HIV RNA copies per ml in index partner§ 200 (ND-8876) 8972 (1069-41359) ND <0.001
Detectable plasma HIV RNA in index case§ 143 (54) 111 (93) 30 (21) <0.001
History of AIDS defining condition 107 (17) 43 (9.0) 57 (38) <0.001
Current sexually transmitted infection in either partner 33 (5.1) 26 (5.5) 6 (4.0) 0.7
Current bacterial vaginosis or vaginal candidiasis in the woman 100 (15) 72 (15) 16 (11) 0.2
Period 1997-2008 (combined treatment available) 296 (46) 143 (30) 149 (100) <0.001
HIV infection in non-index partner 46 (7.1) 44 (9.2) 0 <0.001
IQR=interquartile range; ND=non-detectable plasma HIV RNA.
*Couples with index case taking monotherapy or dual therapy are not shown.
†P values were obtained from Fisher’s exact test or Wilcoxon’s test.
‡Available for 573 patients.
§Available for 267 patients.
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0.33, 0.67, and 1, respectively. Vaginal or anal inter-
course without a condom was considered to be a “sex-
ual risk practice.”“ Risky sexual exposures” included
sexualriskpracticesandcondombreakageorslippage
during intercourse.
For each visit we categorised couples according to
antiretroviral therapy of the index partner: not taking
antiretroviral treatment, taking monotherapy/dual
therapy, and taking combined therapy with at least
three active drugs. Only treatments taken for at least
three months were considered.
Laboratory tests
At baseline and every visit thereafter each partner pro-
videdavenousbloodsample.Non-indexpartnerswere
tested to determine serum antibodies to HIV-1/2, and
reactive samples were confirmed by western blotting.
Syphiliswasroutinelyevaluatedwithareaginictestand
by Treponema pallidum passive particle agglutination
assay or the fluorescent treponema antibody absorp-
tion test. Men were evaluated if they had symptoms of
asexuallytransmittedinfectionorifonehadbeendiag-
nosed in their partner. Gynaecological examinations
includedscreeningforinfectionsincervicalandvaginal
exudates. CD4 count in the index partner was deter-
mined by flow cytometry and plasma HIV RNA by a
branchedDNAassay.Thelowerlimit ofdetectionwas
500 copies per ml until 1999, and 50 copies per ml
thereafter.
Statistical analysis
We estimated HIV seroprevalence at enrolment, the
incidence rate of seroconversion by couple years of
follow-up, and the probability of transmission per sex-
ual risk exposure. We compared estimates for couples
in which the index partner was taking combined anti-
retroviral therapy with those for couples in which the
index partner was not receiving any antiretroviral
treatment. In the follow-up analysis, we evaluated
HIV seroconversions per couple years and per sexual
risk exposures between two successive visits with
respect to sexual behaviours, antiretroviral treatment,
and characteristics of the couple reported for that spe-
cific period. Index partners who started or changed
antiretroviral treatment between two successive visits
were classified in the lower treatment category. Geni-
tourinary infections and other circumstances detected
at a visit were considered as covariates present during
the whole time period since the previous visit.
We compared continuous variables with the Wil-
coxon test, proportions with Fisher’s exact test, and
rates with exact methods. Confidence intervals for
rates were calculated by assuming a Poisson distribu-
tion, and confidence intervals for risks by assuming a
binomial distribution.
RESULTS
Prevalence of HIV infection at recruitment
Between 1989 and 2008, we recruited 648 heterosex-
ual couples in which only one partner had previously
received a diagnosis of HIV-1 infection. The median
length of the relationship was 3.1 years, and in 535
(83%)couplestheindexpartnerwastheman.Seropre-
valence in the non-index partners of these couples was
11% (38/352) in 1989-96 and 2.7% (8/296) in 1997-
2008, when combined antiretroviral therapy became
available (P<0.001). In 476 couples (73%) the index
partner was not taking antiretroviral treatment: 333
because this was before antiretrovirals became avail-
able, 99 who did not meet the criteria for treatment,
21 who were still under evaluation, and 23 who
declined treatment. In 23 couples the index partner
was taking monotherapy or dual therapy, and in 149
couples he or she was taking combined antiretroviral
treatment.
Index partners who were taking combined anti-
retroviral treatment had a significantly longer known
duration of HIV infection than those not taking any
antiretroviral treatment and had more often begun
the relationship with their partner after the diagnosis
of HIV or AIDS defining diseases. In those in whom
wecoulddetermineviralload,itwasdetectablein93%
(111/120) of those who were not taking antiretroviral
treatment compared with 21% (30/145) of those who
were taking combined treatment (P<0.001). The pro-
portionofthosewhohadhadunprotectedsexualinter-
course in the past six months was slightly lower in
couples in which the index partner was taking
combined antiretroviral treatment (273/476 (57%)
v 69/149 (46%), P=0.019), as was the proportion of
couples with previous pregnancies (226/476 (47%)
v 53/149 (36%), P=0.011) (table 1).
TheprevalenceofHIV-1infectionwas9.2%(44/476)
among partners of index partners who were not taking
antiretroviral treatment and 8.7% (2/23) in partners of
index partners taking monotherapy/dual therapy; no
HIV infection was detected in partners of index
partners taking combined therapy (0/149; P<0.001)
(figure). The stratified analyses ruled out the main
Couples fulfilling inclusion criteria (n=648)
HIV serodiscordant couples at first visit (n=602)
HIV serodiscordant couples with follow-up (n=424)
HIV infected
partners (n=44)
HIV infected
partners (n=2)
HIV infected
partners (n=0)
Index partner not
taking antiretroviral
treatment (n=476)
Index partner
taking monotherapy/
dual therapy (n=23)
Index partner taking
combined antiretroviral
therapy (n=149)
Index partner not taking
antiretroviral treatment
(863 couple years)
Index partner taking
monotherapy/dual therapy 
(75 couple years)
Index partner taking combined
antiretroviral therapy  
(417 couple years)
Transmission events (n=5) No transmission event No transmission event
Study scheme of couples included in each analysis
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association (table 2).
HIV-1 transmission during follow-up
We evaluated HIV-1 transmission in the 424 couples
who were initially serodiscordant and who had at least
one follow-up visit between 1989 and 2008 (figure). A
total of 1355 couple years of follow-up were accrued,
with about 95000 acts of intercourse, in which a con-
domwasnotusedinabout20000.Duringoneormore
follow-up periods, 266 couples (63%) reported sexual
risk exposures, and 88 had pregnancies by natural
methods. About 20% of couples (n=86) met criteria
for censored follow-up (five HIV seroconversions, 23
deathsofapartner,46endedrelationships,and12non-
index partners who had had sexual contacts with
another person); 249 (59%) did not return for check
up in 24 months with no known cause; and 89 (21%)
were still in follow-up at the end of the study.
There were about 11000 sexual risk exposures in
863 couple years when the index partner was not
taking antiretroviral treatment. Genitourinary infec-
tion was detected in 61 couples (18%), and the median
plasmaHIVRNAconcentrationinindexpartnerswas
6402 copies per ml (interquartile range 500-42916).
There were 50 natural pregnancies and five HIV sero-
conversions, which represents an incidence of 0.6 per
100 couple years and a probability of transmission of
0.0004perunprotectedcontact(95%confidenceinter-
val,0.0001to0.0010).Ofthesecouples,294(86%)had
always used condoms during intercourse between at
least two successive visits, accruing 627 couple years
of follow-up and about 42000 episodes of intercourse
with condoms; there were 136 instances of condoms
breakingorslippingduringintercourse(threeacciden-
tal exposures per 1000 sexual relations with condom).
Onlytwoofthesusceptiblepartnerstookantiretroviral
prophylaxis after these accidental exposures. Six of
these events coincided with natural pregnancies and
one with HIV seroconversion, which represents a
probability of transmission of 0.000024 per contact
with a condom (0.000001 to 0.000153). The relative
Table 2 |Prevalence of HIV infection at first visit among heterosexual partners of index partner with HIV, according to
selected characteristics of couple. Figures are numbers and percentages.
Population analysed
No antiretroviral treatment Combined antiretroviral treatment
P value* Infected/analysed HIVprevalence(%) Infected/analysed HIVprevalence(%)
All partners 44/476 9 0/149 0 <0.001
Sex of index partner:
Male 38/385 10 0/130 0 <0.001
Female 6/85 7 0/19 0 0.6
Beginning of relationship:
After HIV diagnosis in index partner 11/164 7 0/103 0 0.008
Before HIV diagnosis in index partner 33/312 11 0/46 0 0.01
Time since beginning of relationship (years):
<5 27/305 9 0/85 0 0.001
≥5 14/171 10 0/64 0 0.005
Previous pregnancy in woman:
No 16/254 6 0/96 0 0.008
Yes 28/222 13 0/53 0 0.004
Plasma HIV RNA in index partner:
Not detectable 0/9 0 0/115 0 NA
Detectable 6/110 6 0/30 0 0.3
Not available 38/357 11 0/4 0 1
CD4 cell count per ×10
6/l in index partner:
<200 11/58 19 0/15 0 0.1
≥200 18/352 5 0/130 0 0.005
Not available 15/66 23 0/4 0 0.6
AIDS defining conditions in index partner:
No 33/433 8 0/92 0 0.003
Yes 11/43 26 0/57 0 <0.001
Genitourinary infection in either partner:
No 35/383 9 0/129 0 <0.001
Yes 9/93 10 0/20 0 0.4
Period:
1989-96 36/334 11 0/0 NA NA
1997-2008 (combined treatment
available)
8/142 6 0/149 0 0.003
NA=not available (could not be calculated).
*P values obtained from two sided Fisher’s exact test.
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dom compared with intercourse without a condom
was 0.07 (0.01 to 0.58; P=0.008).
In 144 couples the index partner was taking com-
bined antiretroviral treatment during 417 couple
years,accruingover7000sexual riskexposures.Geni-
tourinary infections were diagnosed in eight couples
(6%), and 92% (112/122) of index partners had unde-
tectable plasma HIV RNA. During follow-up, 47 nat-
ural pregnancies occurred, but no seroconversion was
detected (table 3). This provides an upper limit of the
95% confidence interval for the probability of trans-
mission of 0.0005 per unprotected relationship.
Therewas,however,nosignificantdifferencebetween
this probability and the probability of transmission
when the index partner was not taking antiretroviral
treatment (P=0.16).
Characteristics of couples with HIV transmission
HIVtransmissionwasdetectedin46couplesatthefirst
visit and in five more couples during follow-up
(table 4). Two of the 51 index partners were being
treated with one antiretroviral drug, but none was
receiving combined antiretroviral treatment. Two
couples had not reported any unprotected intercourse
and transmission was associatedwith a condom failing
during intercourse; neither of these partners received
antiretroviralprophylaxisafterexposure.Infourofthe
51 couples with transmission, the diagnosis of HIV
coincided with a natural pregnancy. In 12 couples
(29%) one or both partners had genitourinary infec-
tions, and 12 index partners had been diagnosed with
AIDS defining conditions. The eight transmitter part-
ners in whom plasma HIV RNA was measured had a
detectable concentration, with a range of 362-214400
copies per ml.
DISCUSSION
Principal findings
ThisstudyevaluatedHIV-1transmissioninstablehet-
erosexual serodiscordant couples, with prospective
recording of risk exposures and other relevant factors.
No index partner who was taking combined anti-
retroviral treatment transmitted the infection to his or
her partner after 417 couple years of follow-up. This
does not rule out the possibility of heterosexual trans-
missionfrompeopletakingthistreatment,butitallows
us to establish, with less than 5% error, that the
Table 3 |Characteristics of couples and events occurring during follow-up according to antiretroviral treatment of index partner
All couples
Antiretroviral treatment of index partner*
Without
treatment
Monotherapy/
dual therapy
Combined
treatment
Couples in follow-up:
All 424 341 47 144
Male index partner (%) 351 (83) 279 (82) 33 (70) 117 (81)
Couple years 1355 863 75 417
Estimated No of coital acts 95 000 62 000 5000 28 000
Couples with sexual risk exposures during follow-up†:
Couples with unprotected sexual contacts (%) 266 (63) 187 (55) 24 (51) 101 (70)
Couples with unprotected penile-anal contacts 26 13 4 11
Estimated No of risky sexual exposures 20 000 11 000 1600 7400
No of condom failures during intercourse 198 166 14 18
Womenwithbacterialvaginosisorvaginalcandidiasis 61 53 9 6
Sexually transmitted infection in either partner‡ 981 2
History of AIDS defining disease in index partner 55 19 13 35
First year of relationship 62 54 0 8
Index partner with primary infection 3 3 0 0
Plasma HIV RNA (undetectable/tested (%)) 142/220 (65) 28/95 (29) 6/14 (43) 112/122 (92)
Median (IQR) plasma HIV RNA copies per ml ND (ND-6900) 6402 (500-42 916) 5367 (ND-16 770) ND
Seroconversions to HIV in follow-up:
No of seroconversions 5 5 0 0
Percentage of couples (95% CI) 1.2 (0.4 to 2.7) 1.5 (0.5 to 3.4) 0 (0 to 7.5) 0 (0 to 2.5)
Rate per 100 couple years (95% CI) 0.4 (0.1 to 0.9) 0.6 (0.2 to 1.4) 0 (0 to 6.1) 0 (0 to 1.1)
Transmission per 1000 risk exposures (95% CI) 0.2 (0.1 to 0.6) 0.4 (0.1 to 1.0) 0 (0 to 2.2) 0 (0 to 0.5)
Natural pregnancies during follow-up:
No of couples with any natural pregnancy 88 48 4 39
Percentage (95% CI) 21 (17 to 25) 14 (11 to 18) 9 (2 to 20) 27 (20 to 35)
No of natural pregnancies 101 50 4 47
Rate per 100 couple years (95% CI) 7.5 (6.1 to 9.0) 5.8 (4.4 to 7.6) 5.3 (1.7 to 13.8) 11.3 (8.5 to 14.8)
ND=not detectable.
*Each couple could have different therapeutic options during follow-up.
†Includes penile-vaginal or penile-anal contacts without condom and condoms breaking or slipping during intercourse.
‡Condylomata acuminata (8) and urethritis (1).
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that the rate of seroconversion is less than 1 in 91 cou-
ple years. Moreover, we found no case of HIV trans-
mission in the 149 couples at the first visit in which the
indexpartnerwastakingcombinedantiretroviralther-
apy.PlasmaHIVRNAwasundetectableinmostindex
partners taking combined antiretroviral treatment,
which shows good control of viral replication. The
viral load in genital secretions seems to fall together
with the viral load in plasma after combined
therapy,
1617 and this would explain a reduction in
infectivity.
6
Inthesameprogramme,amongattendingcouplesin
whichtheindexpartnerwasnottakingcombinedanti-
retroviral therapy, we detected 46 HIV infections in
the non-index partner at the first visit and five during
follow-up. In the prospective analysis, condom use in
allactsofintercoursereducedtheriskofHIVtransmis-
sion to the partner by 93% (95% confidence interval
42% to 99%) when the index partner was not taking
antiretroviral treatment.
Comparison with other studies
The incidence of HIV infection found during follow-
up in partners whose index partners were not taking
combined antiretroviral treatment was lower than
that reported in other studies.
22 The probability of
transmission from risk exposure in the follow-up was
similar to or slightly lower than that described in stu-
dies in developed countries
1-310 and much lower than
in developing countries.
4-68 The protective effect asso-
ciated with condom use was within the range of that
described in the literature.
14
Although we did not find a single case of HIV trans-
mission when the index partner was taking combined
antiretroviraltherapy,theexistenceofsomeriskcould
not be totally ruled out as the persistence of HIV in
genital secretions or transient increases in viral load
in patients taking combined antiretroviral treatment
and long term suppression of the viral load in plasma
havebeendescribed.
1625-28SexualtransmissionofHIV
from an infected partner taking antiretroviral therapy
withrepeatedlyundetectableplasmaviralloadhasalso
been documented.
29
Strengths and limitations
Participants were recruited within a programme offer-
ing preventive counselling, as well as diagnosis and
treatment of genitourinary infections. During follow-
up almost half of the couples discontinued their risk
behaviour, and many others began to use condoms
for most acts of intercourse. This would explain why
the incidence rates during follow-up were lower than
those that could be estimated from the cases of trans-
mission detected at the first visit, before any influence
of the intervention. Moreover, the infections detected
atthefirstvisitwouldincludemorevulnerablecouples
who rapidly become seroconcordant, whereas follow-
up might over-sample less susceptible partners or less
infective index partners.
30
The couples in which the index partner was taking
combined antiretroviral therapy were not completely
comparable with those in which the index partner was
nottakinganyantiretroviraltreatment,giventhatanti-
retroviral therapy is prescribed for patients with worse
clinical states,
24 who are therefore more infectious for
their sexual partners.
67
Although this is one of the studies with the largest
number of couples and longest follow-up time of
those conducted in developed countries, there was
insufficient statistical power for some of the analyses,
especially in situations with a low probability of trans-
mission. Nevertheless, the number of exposures dur-
ing follow-up was considerable, as shown by the 101
natural pregnancies that were registered.
Given the inclusion criteria, we can state with a high
level of probability that the HIV infections detected in
non-index partners were attributable to heterosexual
transmission from the index partner. Caution advises
us against generalising these results to casual partners
or to homosexual relationships between men, given
the more frequent circumstances favouring transmis-
sion,suchasanalsex,presenceofsexuallytransmitted
infections, or early stage of infection.
1-8
Analysis of self reported sexual behaviour data
based on six month recall requires some caution. The
quantification of exposures without condoms might
also have been subject to some error as they were
basedonacategoricalvariable.Inthe contextofapre-
ventive intervention, the use of condoms might have
been over-reported, leading to a higher estimate of
Table 4 |Characteristics of 51 couples at diagnosis of HIV infection in non-index partner.
Figures are numbers (percentages) of participants or median (interquartile range)
All couples No (%)
Characteristics of index partner:
Male 44 (86)
Injecting drug user 41 (80)
Median (IQR) time since HIV diagnosis (months) 8 (1-51)
Median (IQR) last CD4 cell count ×10
6/l (n=36) 233 (99-362)
Median (IQR) last plasma HIV RNA copies per ml (n=8) 54 266 (21 264-163 049)
AIDS defining diseases 12 (24)
Antiretroviral treatment:
Monotherapy 2 (4)
No 49 (96)
Characteristics of couple and relationship:
Median (IQR) age (years):
Men 30 (28-33)
Women 26 (22-32)
Median (IQR) time of relationship (years) 3.8 (1.5-7.9)
Began relationship after HIV diagnosis in index partner 15 (29)
Penile-vaginal contacts without condom 49 (96)
Penile-anal contacts without condom 15 (29)
Failure of condom during intercourse as sole risk exposure 2 (4)
Pregnancy in woman 4 (8)
Genitourinary infection in either partner 12 (24)
Transmission detected during combined antiretroviral treatment
period
10 (20)
Transmission detected at first visit 46 (90)
IQR=interquartile range.
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condom failures was underestimated; however, the
information was collected before the non-index part-
ner’s serological state was known, which reduces dif-
ferential biases. Condom use might be more common
insexualrelationshipsinwhichthereareotherconcur-
rentrisk factors—that is,higherrisk practices,sexually
transmitted infections, and high viral load in the index
partner.
TherewerenocasesofHIVtransmissionfromindex
partners who were taking combined antiretroviral
treatment, making it impossible for us to adjust multi-
variate models that control for potential confounders;
consequently,westratifiedbythesefactorsintheretro-
spective analysis to rule out a confounding effect was
causingafalseassociationbetweenantiretroviraltreat-
ment in the index partner and lower HIV seropreva-
lence in the couple.
Because this was a convenience cohort, with no
incentives provided, the number of couples who
dropped out without explanation was high. These
dropouts are an important limitation in follow-up stu-
dies and can invalidate the results if they are related to
HIV seroconversion in the non-index partner.
Although the reason for not returning to the clinic
could not be established in a large proportion of cou-
ples,weconsideritwasunlikelytoberelatedwithHIV
seroconversion in the partner as the study was carried
outinthemostactiveandaccessibleHIVtestingcentre
in the region.
Conclusions and implications
Although we cannot rule out the possibility of hetero-
sexualtransmissionfrompeoplewithHIVtakingcom-
binedantiretroviraltherapy,ourresultsshowthatwith
these treatments the risk of transmission is probably
low. Consistent condom use can have a considerable
preventive impact in the population, although HIV
transmission is possible with condom failure during
intercourse in serodiscordant couples. As to date no
single measure has been able to guarantee the absence
of the risk of HIV transmission during intercourse
betweenserodiscordantheterosexualcouples,thecon-
trol of genitourinary infections, avoidance of unpro-
tected intercourse, and antiretroviral treatment in the
index partner in accordance with protocols should be
considered as complementary measures.
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